|"Making it easier to self carry life saving medicines ON you at ALL times"
Auvi-Q now available in the US
January 28, 2013
Sanofi announced today that Auvi-Q™ (epinephrine injection, USP) is
now available in U.S. retail pharmacies nationwide with a prescription
from a healthcare provider.
Auvi-Q is the first-and-only epinephrine auto-injector with audio and
visual cues for the emergency treatment of life-threatening allergic
reactions in people who are at risk for or have a history of anaphylaxis.
The size and shape of a credit card and the thickness of a smart
phone, Auvi-Q is a breakthrough in epinephrine auto-injector device
design that talks patients and caregivers step-by-step through the
"Patient feedback was a critical component to the development
process for Auvi-Q," said Anne Whitaker, President, North America
Pharmaceuticals, Sanofi. "The availability of Auvi-Q represents an
important step forward in our continued innovation to meet the needs
of people at risk for anaphylaxis and their caregivers."
SANOFI AUVI-Q(TM)Up to six million Americans may be at risk for
anaphylaxis, although the precise incidence is unknown and likely
under-reported. While guidelines emphasize the importance of the life-
saving role of epinephrine, two large surveys show that two-thirds of
patients and caregivers do not carry their epinephrine auto-injectors
as recommended, and nearly half worry that others will not know how
to use their or their child's epinephrine auto-injector correctly during
Multiple studies have found an association between delay in
epinephrine administration and death from anaphylaxis. Life-
threatening allergic reactions may occur as a result of exposure to
allergens including foods such as peanuts, tree nuts, fish, shellfish,
dairy, eggs, soy and wheat; insect stings; latex and medication, among
other allergens and causes.
- The new Auvi-Q is smaller making it easier
to carry but it is important to ensure
- Dr's recommend you carry two epinephrine
auto injectors at all times.
- Self carry two Auvi-Q inside secured pant
pockets, an undergarment holder, or a
carrier that can be attached or clip on to
The signs and symptoms of anaphylaxis can vary from person to person and from one
episode to the next. Some people may have hives/itching, facial or tongue swelling, which
makes it difficult to breathe or swallow, while others may experience nausea and vomiting.
These symptoms may begin within seconds, minutes or hours after exposure to the allergen.
When a severe, life-threatening allergic reaction occurs, epinephrine should be
administered immediately and patients and caregivers should seek immediate medical
attention. Patients and caregivers should always carry and know how to use an epinephrine
auto-injector to treat emergency allergic reactions. Without treatment, anaphylaxis can result
in death within a matter of minutes.
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of
healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative
drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is
listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi is the holding company of a consolidated group of subsidiaries and operates in the
United States as Sanofi US, also referred to as Sanofi-aventis U.S. LLC. For more
information on Sanofi US, please visit Sanofi or call 1-800-981-2491.
Auvi-Q (epinephrine injection, USP) is
used to treat life-threatening allergic at
risk for or have a history of these
Important Safety Information
Auvi-Q is for immediate self (or caregiver)
administration and does not take the
place of emergency medical care. Seek
immediate medical treatment after use.
Each Auvi-Q contains a single dose of
Auvi-Q should only be injected into your
outer thigh. DO NOT INJECT INTO
BUTTOCK OR INTRAVENOUSLY. If you
accidentally inject Auvi-Q into any other
part of your body, seek immediate medical
treatment. Epinephrine should be used
with caution if you have heart disease or
are taking certain medicines that can
cause heart-related (cardiac) symptoms.
If you take certain medicines, you may
develop serious life-threatening side
effects from epinephrine. Be sure to tell
your doctor all the medicines you take,
especially medicines for asthma. Side
effects may be increased in patients with
certain medical conditions, or who take
certain medicines. These include asthma,
allergies, depression, thyroid disease,
Parkinson's disease, diabetes, high blood
pressure, and heart disease.
The most common side effects may
include increase in heart rate, stronger or
irregular heartbeat, sweating, nausea and
vomiting, difficulty breathing, paleness,
dizziness, weakness or shakiness,
headache, apprehension, nervousness,
or anxiety. These side effects go away
quickly, especially if you rest.
Talk to your healthcare professional to
see if Auvi-Q is right for you.
Auvi-Q provides users with audible and visual cues, including a five-second injection countdown and an alert light to signal when the
injection is complete. Auvi-Q also features an automatic retractable needle mechanism to help prevent accidental needle sticks.
Available in two different dosages, Auvi-Q 0.3mg delivers 0.3mg epinephrine injection and is intended for patients who weigh 66 pounds
or more. Auvi-Q 0.15mg delivers 0.15mg epinephrine injection and is intended for patients who weigh 33 – 66 pounds. Auvi-Q has not
been studied in patients weighing less than 33 pounds. Each Auvi-Q pack contains two devices - containing one dose of epinephrine
each - and a non-active training device. Auvi-Q received U.S. Food and Drug Administration approval in August 2012.
Sanofi US licensed the North America commercialization rights to Auvi-Q from Intelliject, Inc., which has retained commercialization rights
for the rest of the world. Eric and Evan Edwards, twin brothers who suffer from life-threatening allergies, and co-founders of Intelliject, Inc.,
developed Auvi-Q with a team of world class engineers and scientists. The development process incorporated real-world experiences and
feedback from patients and caregivers.
Auvi-Q has been named an International CES Innovations 2013 Design and Engineering Awards Honoree. The prestigious Innovations
Design and Engineering Awards are sponsored by the Consumer Electronics Association (CEA)®, the producer of the International CES
and the world's largest consumer technology tradeshow CES-Innovations-Awards
|LegBuddy holds two
epinephrine auto injectors
such as Auvi-q or Epipen.
Discreet, convenient, soft
neoprene for 24/7 comfort.